Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin alfa versus placebo for chemotherapy-associated anemia in advanced non-small cell lung cancer
2007-005792-34Phase 3Terminated
- Sponsor
- Amgen
- Start
- Apr 2009
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in anaemia and non-small cell lung cancer (NSCLC) comparing Darbepoetin alfa with Placebo (2 arms). Primary endpoint: Overall survival. Started Apr 2009; status: terminated.
02
Drugs
darbepoetin alfa
03
Conditions
anaemianon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-005792-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005792-34.